Major Clinical Trials in Gastric Cancer
INT-0116 Trial (1997)
Objective: Postoperative chemoradiotherapy in gastric cancer.
Conclusion: Improved overall survival with adjuvant chemoradiotherapy in resected gastric cancer patients.
MAGIC Trial (2006)
Objective: Perioperative chemotherapy vs surgery alone.
Conclusion: Perioperative ECF chemotherapy improved survival compared to surgery alone.
ACTS-GC Trial (2007)
Objective: S-1 adjuvant chemotherapy in Japanese patients after D2 resection.
Conclusion: S-1 improved survival significantly, becoming standard in Japan.
CLASSIC Trial (2012)
Objective: Capecitabine + Oxaliplatin (XELOX) as adjuvant therapy after D2 surgery.
Conclusion: XELOX regimen improved disease-free and overall survival.
FLOT4 Trial (2019)
Objective: FLOT vs ECF/ECX as perioperative chemotherapy.
Conclusion: FLOT regimen significantly improved overall survival and became new standard of care.
CheckMate-649 Trial (2021)
Objective: Nivolumab + chemotherapy vs chemotherapy alone in advanced gastric cancer.
Conclusion: Nivolumab improved OS and PFS in PD-L1 positive patients, changing frontline treatment in advanced disease.